[Determination of TNF-alpha and endotoxemia in patients with chronic liver diseases].
The incidence of endotoxemia in 153 patients with different liver diseases was determined by Limulus Lysaite Test(LLT). Comparative studies were carried out on the levels of tumour necrosis factor-alpha(TNF-alpha) between positive and negative endotoxemia in patients suffering from chronic liver diseases. At the same time, 58 patients of positive endotoxemia were divided into two groups--bifidobiogen group (38 cases) and control group(20 cases). The patients in bifidobiogen group were treated mainly with daily administration of bifidobiogen for 1 month besides general liver--protection therapy and the bifidobiogen was not given to the control group. The results showed that: 1. Incidence of endotoxemia in 153 patients suffering from various types of liver diseases was 65.36%; the highest rate was found in the patients with severe hepatitis; 2. The TNF-alpha level was obviously increased in the patients of positive endotoxemia; 3. The total efficacy in bifidobiogen group was significantly higher than that in control group. The data suggest that chronic liver diseases are generally complicated with endotoxemia, and TNF-alpha plays an important role in the pathogenesis of endotoxemia. The serum endotoxin level may be reduced after the treatment with bifidobiogen.
Xie
J
J
Department of Infectious Diseases, Xiangya Hospital, Hunan Medical University, Changsha 410008.
Lin
M
M
Liu
A
A
Fan
X
X
D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use; D019446:Endotoxemia / Q000209:etiology* / Q000628:therapy; D005260:Female; D019694:Hepatitis B, Chronic / Q000097:blood* / Q000628:therapy; D006801:Humans; D008033:Limulus Test; D008103:Liver Cirrhosis / Q000097:blood* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*
D001688:Biological Products; D014409:Tumor Necrosis Factor-alpha; C010546:bifidobacterin